Compare CDW & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDW | ELAN |
|---|---|---|
| Founded | 1984 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 12.7B |
| IPO Year | 2013 | 2018 |
| Metric | CDW | ELAN |
|---|---|---|
| Price | $136.94 | $23.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $164.88 | $27.89 |
| AVG Volume (30 Days) | 1.3M | ★ 4.3M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 1.38 | N/A |
| EPS | ★ 8.08 | N/A |
| Revenue | ★ $10,768,600,000.00 | $4,715,000,000.00 |
| Revenue This Year | $4.08 | $8.21 |
| Revenue Next Year | $4.01 | $5.31 |
| P/E Ratio | $16.57 | ★ N/A |
| Revenue Growth | ★ 6.32 | 6.22 |
| 52 Week Low | $112.98 | $8.59 |
| 52 Week High | $189.45 | $27.72 |
| Indicator | CDW | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 72.83 | 48.86 |
| Support Level | $137.08 | $22.17 |
| Resistance Level | $150.48 | $23.70 |
| Average True Range (ATR) | 3.20 | 0.90 |
| MACD | 1.53 | 0.05 |
| Stochastic Oscillator | 100.00 | 63.87 |
CDW Corp is a multi-brand provider of information technology (IT) solutions to businesses, government, education, and healthcare customers in the United States, the United Kingdom, and Canada. The company's offerings range from hardware and software products to integrated IT solutions and services, including on-premise and cloud capabilities across hybrid infrastructure, digital experience, and security. Its reportable segments are Corporate, Small Business, Public, and Other. The Corporate and Small Business segments serve US private sector business customers, while the Public segment consists of government agencies and education and healthcare institutions in the US. The Corporate segment generates the majority of its revenue in the United States.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.